CymaBay Therapeutics, Inc.

( )
CBAY After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.80%69.520.0%$2233.03m
NVAXNovavax, Inc. -16.77%124.4299.2%$975.55m
SRNESorrento Therapeutics, Inc. -11.92%12.411.5%$660.63m
GILDGilead Sciences, Inc. 1.09%68.841.0%$572.71m
AMGNAmgen, Inc. 3.01%241.721.3%$487.38m
REGNRegeneron Pharmaceuticals, Inc. 2.25%612.352.7%$403.88m
VRTXVertex Pharmaceuticals, Inc. 3.43%270.851.9%$372.31m
BNTXBioNTech SE 0.96%69.110.0%$367.35m
BIIBBiogen, Inc. 1.13%293.221.6%$358.10m
ILMNIllumina, Inc. 0.86%344.143.5%$335.56m
VXRTVaxart, Inc. -14.42%9.200.0%$307.65m
ATNMActinium Pharmaceuticals, Inc. -0.31%9.6313.3%$235.99m
EBSEmergent BioSolutions, Inc. 6.00%129.676.4%$186.47m
ALXNAlexion Pharmaceuticals, Inc. 1.52%102.782.0%$167.42m
SGENSeattle Genetics, Inc. 3.46%158.796.2%$160.84m

Company Profile

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.